Banco Bilbao Vizcaya Argentaria S.A. Has $2.59 Million Position in DaVita Inc. (NYSE:DVA)

Banco Bilbao Vizcaya Argentaria S.A. cut its holdings in DaVita Inc. (NYSE:DVA) by 0.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 17,330 shares of the company’s stock after selling 110 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in DaVita were worth $2,592,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Invesco Ltd. increased its holdings in shares of DaVita by 20.9% in the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company’s stock valued at $237,716,000 after purchasing an additional 275,284 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after buying an additional 92,014 shares during the period. Amundi raised its position in shares of DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after acquiring an additional 240,126 shares during the last quarter. Epoch Investment Partners Inc. acquired a new position in shares of DaVita during the fourth quarter valued at $55,100,000. Finally, KBC Group NV boosted its holdings in DaVita by 0.8% in the fourth quarter. KBC Group NV now owns 316,155 shares of the company’s stock valued at $47,281,000 after acquiring an additional 2,636 shares during the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

DVA opened at $139.57 on Friday. The stock has a market cap of $11.17 billion, a P/E ratio of 13.00, a P/E/G ratio of 1.07 and a beta of 1.04. DaVita Inc. has a 12 month low of $131.27 and a 12 month high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The company has a fifty day simple moving average of $146.50 and a 200 day simple moving average of $155.27.

DaVita (NYSE:DVA) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, research analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Cowen restated a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. StockNews.com raised shares of DaVita from a “hold” rating to a “buy” rating in a research note on Friday. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. Finally, Barclays raised their price target on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.